Research Tools; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.